- Home
- CDE vs AZTA Comparison
CDE vs AZTA Comparison
Compare CDE & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDE
- AZTA
- Stock Information
- Founded
- CDE 1928
- AZTA 1978
- Country
- CDE United States
- AZTA United States
- Employees
- CDE N/A
- AZTA N/A
- Industry
- CDE Precious Metals
- AZTA Industrial Machinery/Components
- Sector
- CDE Basic Materials
- AZTA Technology
- Exchange
- CDE Nasdaq
- AZTA Nasdaq
- Market Cap
- CDE 2.5B
- AZTA 2.4B
- IPO Year
- CDE N/A
- AZTA 1995
- Fundamental
- Price
- CDE $6.17
- AZTA $52.63
- Analyst Decision
- CDE Strong Buy
- AZTA Buy
- Analyst Count
- CDE 4
- AZTA 5
- Target Price
- CDE $7.81
- AZTA $61.60
- AVG Volume (30 Days)
- CDE 9.8M
- AZTA 595.5K
- Earning Date
- CDE 02-19-2025
- AZTA 02-05-2025
- Dividend Yield
- CDE N/A
- AZTA N/A
- EPS Growth
- CDE N/A
- AZTA N/A
- EPS
- CDE N/A
- AZTA N/A
- Revenue
- CDE $1,010,652,000.00
- AZTA $656,323,000.00
- Revenue This Year
- CDE $32.61
- AZTA N/A
- Revenue Next Year
- CDE $39.85
- AZTA $6.32
- P/E Ratio
- CDE N/A
- AZTA N/A
- Revenue Growth
- CDE 31.38
- AZTA N/A
- 52 Week Low
- CDE $2.42
- AZTA $38.82
- 52 Week High
- CDE $7.72
- AZTA $69.16
- Technical
- Relative Strength Index (RSI)
- CDE 49.13
- AZTA 64.67
- Support Level
- CDE $5.90
- AZTA $50.79
- Resistance Level
- CDE $6.60
- AZTA $53.47
- Average True Range (ATR)
- CDE 0.30
- AZTA 1.78
- MACD
- CDE 0.04
- AZTA 0.01
- Stochastic Oscillator
- CDE 56.64
- AZTA 75.83
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.